Humacyte (HUMA) announced the first sale of Symvess to a U.S. Military Treatment Facility. The facility is a state-of-the-art medical complex located on a major U.S. military base that provides health care to approximately 200,000 active-duty service personnel, retirees, and their family members. This sale follows the recent ECAT listing approval from the U.S. Defense Logistics Agency. The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at approximately 35 Military Treatment Facilities and approximately 160 U.S. Department of Veterans Affairs hospitals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
- Humacyte’s Symvess awarded Electronic Catalog listing approval by DoD
- Humacyte’s Symvess: A Promising Solution for Hemodialysis Challenges with Buy Rating
- Humacyte Approves Key Proposals at Annual Meeting
- Humacyte announces presentation of results from Phase 3 AV access study of V007